Epidemiologie der Psoriasis in Deutschland - Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung

Schäfer, Ingmar; Rustenbach, Stephan Jeff; Radtke, Marc Alexander; Augustin, Jobst; Glaeske, Gerd; Augustin, M.

doi:10.1055/s-0030-1252022

Cited by 75 publications

(60 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For other skin diseases, population-based studies on prevalence are sparser. However, our results are in agreement with prevalence data published for psoriasis (29)(30)(31)(32)(33), atopic eczema (23,27,(34)(35)(36)(37) and acne (25,(38)(39)(40). Answers to our question on eczema on other locations than hands may include eczemas other than atopic eczema.…”

Section: Discussionsupporting

confidence: 92%

Self-reported Skin Diseases, Quality of Life and Medication Use: A Nationwide Pharmaco-epidemiological Survey in Sweden

Lindberg¹,

Isacson²,

Bingefors³

2014

Acta Derm Venerol

View full text Add to dashboard Cite

The aim of this study was to determine self-reported consumption of dermatological pharmaceuticals and quality of life (QoL), measured with Short Form 36, in relation to eczema, acne, psoriasis and other inflammatory skin conditions in the Swedish population. A questionnaire containing questions on the occurrence of skin diseases, health-related QoL and the use of pharmaceuticals was sent to a cross-sectional sample of the Swedish population, age range 18-84 years (n = 8,000). The response rate was 61%. The 1-year prevalence of skin diseases was 30-35%, with females reporting a higher prevalence. The prevalence was 11.5% for eczema other than hand eczema, 10.2% for acne, 7.5% for hand eczema, 3.9% for psoriasis and 3.1% for urticaria. QoL was significantly affected and 25% of females and 19% of males had used a dermatological drug. Compared with hand eczema, persons with psoriasis and other eczema reported significantly more use of topical steroids on prescription and more use of dermatological pharmaceuticals in total. Skin conditions are common; they affect QoL and lead to a high consumption of dermatological drugs; which deserves increased awareness in the society.

show abstract

Section: Discussionsupporting

confidence: 92%

Self-reported Skin Diseases, Quality of Life and Medication Use: A Nationwide Pharmaco-epidemiological Survey in Sweden

Lindberg¹,

Isacson²,

Bingefors³

2014

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…Furthermore, patients with milder disease who are under the care of a general practitioner or family doctor were not included. The results of regional variation in prescription practices for psoriasis patients are supported by the Gmünd Statutory Health Insurance data from nearly 34 000 psoriasis patients nationwide, with similar differences seen when classified by zip code [22]. Nevertheless, the analysis presented here is largely explorative in nature.…”

Section: Discussionsupporting

confidence: 58%

How do regional factors influence psoriasis patient care in Germany?

Radtke

Augustin

Blome

et al. 2010

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Background: Two national surveys conducted in 2005 and 2007 indicated deficits in psoriasis care in Germany, although there has been a notable nationwide improvement within this period. It remained unclear whether regional differences in psoriasis health care have an influence on patient outcomes in Germany. Aim: Assessment of regional differences in the health care situation of patient with psoriasis in Germany. Patients and Methods: Nation‐wide cross‐sectional study in 130 dermatological practices and clinics. Regional classification was based on the affiliation to the Associations of Statutory Health Insurance Physicians. A panel of experts developed eight criteria as indicators of quality of care, among them clinical characteristics and severity of psoriasis (PASI), previous treatments, quality of life and patient‐relevant therapeutic benefits. Results: Care indicators showed marked regional differences. The proportion of patients with preceding systemic or biologic treatment varied between regions. Those regions with high proportions had better results in patient‐reported outcomes. Conclusions: Differences in economic and regulatory conditions of health care might account for the observed regional variations. Thus, further analyses of these factors are of great importance to assure consistent psoriasis health care in Germany.

show abstract

“…The approximation of the total number of children and adolescents with psoriasis in the SHI was based on the official record type of the German annual compensation statistic for 2007 (German “Satzart [SA] 40,” official statistic of the Federal Insurance Office). For prevalence, the equation for the approximation of a binomial confidence interval (CI; formula 1) was used :

p_{1, 2} = r \pm z_{1 - α / 2} * \sqrt{\frac{r (1 - r)}{n - 1}} with p = r = \frac{k}{n},

where α = alpha error, k = successes in the sample, n = sample size, p = proportion of successes estimated from the statistical sample, r = relative frequency = k / n , and z = number of standard deviations from the mean ( z ‐score). The Anatomical Therapeutic Chemical (ATC) Classification System (2007) was used to classify drugs.…”

Section: Methodsmentioning

confidence: 99%

Childhood Psoriasis—An Analysis of German Health Insurance Data

Matusiewicz

Koerber

Schadendorf

et al. 2013

Pediatric Dermatology

View full text Add to dashboard Cite

This study explored the epidemiology, treatment, and comorbidities of juvenile psoriasis in Germany using health insurance data. Psoriasis is a chronic inflammatory skin condition that affects approximately 2% to 3% of the world's population. Data were obtained from a database of approximately 6.7 million individuals registered with health insurance organizations throughout Germany. The analysis considered all individuals age 18 years and younger with psoriasis who were registered in 2007. Comorbidities were identified using software based on a morbidity-based risk adjustment model. A total of 138,338 patients with a diagnosis of psoriasis were identified in the database, yielding a prevalence of 2.1%. Within this group there were 4,499 children and adolescents (≤ 18 years of age), a prevalence of 0.4%. The prevalence ranged from 0.1% at the age of 1 year to 0.8% at the age of 18 years. Most of the patients were treated with topical corticosteroids (72.2%) and antipsoriatics (e.g., tars, psoralen; 20.0%). Immunosuppressants were used in 3.3% of the cases. Juvenile psoriasis was associated with numerous significant comorbidities such as rheumatoid arthritis and inflammation (2.1%); delirium, psychosis, and psychotic and dissociative disorder (1.1%); and heart disease (0.6%). Our study demonstrated that psoriasis is more prevalent in children and adolescents than some older international investigations have documented. Analysis of the health insurance data showed that juvenile psoriasis is associated with a range of comorbidities. The data also may suggest an unrecognized burden of mental health problems in young persons with psoriasis.

show abstract

Epidemiologie der Psoriasis in Deutschland - Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung

Cited by 75 publications

References 9 publications

Self-reported Skin Diseases, Quality of Life and Medication Use: A Nationwide Pharmaco-epidemiological Survey in Sweden

Self-reported Skin Diseases, Quality of Life and Medication Use: A Nationwide Pharmaco-epidemiological Survey in Sweden

How do regional factors influence psoriasis patient care in Germany?

Childhood Psoriasis—An Analysis of German Health Insurance Data

Contact Info

Product

Resources

About